Altamira Therapeutics Announces IND Clearance By FDA For AM-125 In Acute Vestibular Syndrome
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics has received IND clearance from the FDA for AM-125 in treating acute vestibular syndrome. This approval allows the company to proceed with clinical trials.
June 15, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altamira Therapeutics' FDA IND clearance for AM-125 in acute vestibular syndrome treatment may positively impact the company's stock in the short term.
The FDA IND clearance for AM-125 allows Altamira Therapeutics to proceed with clinical trials, which is a significant milestone for the company. This news may attract investors' attention and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100